


Product Name : TPST-1120
Cat. No. : PC-24111
CAS No. : 1616372-41-8
Molecular Formula : C₃₄H₄₁N₃O₄
Molecular Weight : 555.72
Target : PPAR
Solubility : 10 mM in DMSO



CAS: 1616372-41-8

Biological Activity

Amezalpat (TPST-1120, TPST1120) is potent, selective and orally bioavailable inhibitor of peroxisome proliferator-activated receptor α (PPAR α) with IC₅₀ of 0.04 μ M (human PPAR α), >250-fold selectivity over the other PPAR isoforms (PPAR β/δ and γ).

TPST-1120 exhibits potent anti-tumor immune responses and significant tumor regression in syngeneic models of breast, lung, colon, pancreatic and melanoma in addition to xenograft models of CLL, AML, pancreatic and melanoma cancers as a monotherapy or in combination with chemotherapy.

Combination of TPST-1120 plus anti-PD-1 therapy resulted in synergistic tumor reduction and durable antitumor immunity in multiple syngeneic mouse models.

References

Patent WO2014099503 A1.

Chan C. Whiting, et al. *Cancer Res* (2019) 79 (13_Supplement): 3606.

Mark Yarchoan, et al. *Cancer Res Commun*. 2024 Apr 18;4(4):1100-1110.

US Patent No.676,754 B2. Triazolone compounds and uses thereof; 2017.

Caution: Product has not been fully validated for medical applications. Lab Use Only!

E-mail: tech@probechem.com